Search For
/
Stocks
Intraday Booster
Sector Booster
Stock Screener
Market Pulse
Screeners
More
Go Prime
My Plans
Privacy Policy
Contact
Refer & EarnScreenersMain
Stock Screener
Create Screener
Explore Screeners
Community ScreenersTrading Screeners
CandleSticks Screener
Top Gainers & Losers
Opening Range Breakout
Stock Screener AI
Stock Quality Scorecard
Overvalued StocksNewUndervalued StocksNewTechnical Screeners
NR4 Stocks
NR7 Stocks
Previous Day High Breakout
Previous Day Low Breakout
Previous Day Open Breakout
Bullish Crossover Stocks
Bearish Crossover Stocks
High Volume Shocker
VWAP Breakout Stocks
Range High Breakout
Range Low BreakoutMoreMarkets
Global Market Today
Global Indices
Indian Indices
NIfty TodaySmart Money
FII DII DataNew
FII Buying
NSE Insider Trading
SLB Stocks DataDerivatives
FnO Movements
NSE F&O Lot Size
Ban ListAnalysis & Calendars
Technical DashboardSector Booster
Sector AnalysisNew
Result Calendar
Economic Calendar
Gufic BioSciences
Small Cap•1,491 Employees•IPO 2004
Current Price
₹288.70
14.9 (5.44%)Updated
Today's Range
275.15
₹288.70
297
52 Week Range
52W Low₹268.00
52W High₹407.85
₹288.70
Downside7.72%
Upside41.27%
Price Chart
Compare with Peers
Historical Ratios
Track top 12 most important financial ratios
P/E Ratio: Price to Earnings - Most used valuation metric
Loading chart...
Analyzing Investment Quality
Processing 9 key metrics...
Key Metrics
Hover for details
Valuation
Market Cap
₹2,937.78 Cr
Market Cap
Total market value of companyP/E Ratio
51.41
P/E Ratio
Price to Earnings. Lower is generally better (<25 is good)P/B Ratio
5.63
P/B Ratio
Price to Book Value. <3 may indicate undervaluationEPS
₹5.68
EPS
Earnings Per Share. Higher and growing is positiveProfitability
ROE
3.98%
ROE
Return on Equity. >15% is good, >20% is excellentROCE
13.20%
ROCE
Return on Capital Employed. >15% is goodNet Margin
6.52%
Net Margin
Net profit as % of revenue. >10% is goodOperating Margin
-%
Operating Margin
Operating profit margin. >15% is goodGrowth
EPS Growth (5Y)
24.29%
EPS Growth (5Y)
5-year EPS growth. >15% is strongRevenue Growth (5Y)
16.69%
Revenue Growth (5Y)
5-year revenue growth. >10% is goodQtr Sales Growth
10.30%
Qtr Sales Growth
Quarter-over-quarter sales growthQtr Profit Growth
-37.30%
Qtr Profit Growth
Quarter-over-quarter profit growthFinancial Health
Debt/Equity
0.56
Debt/Equity
Financial leverage. <1 is good, <0.5 is excellentBook Value
₹59.94
Book Value
Net asset value per shareDividend Yield
-%
Dividend Yield
Annual dividend as % of price. >2% is goodPromoter Holding
72.50%
Promoter Holding
Promoter stake. >50% shows confidenceGood
Average
Needs Attention
SWOT Analysis
Strengths
3 points- •Gufic BioSciences demonstrates strong capital efficiency with a 12.3% Return on Equity (ROE) and a 13.2% Return on Capital Employed (ROCE). These metrics highlight the company's effective utilization of shareholder funds and overall capital in generating profits.
- •A substantial promoter holding of 72.5% signals strong confidence from the company's founders and management. This high stake often aligns management's interests with long-term shareholder value, reducing external risks.
Weaknesses
4 points- •Gufic BioSciences trades at a high Price-to-Earnings (P/E) ratio of 53.80, significantly above some industry peers. This elevated valuation suggests the stock might be overvalued, posing a risk for new investors.
- •A concerning 37.30% decline in quarterly profit (PAT) indicates potential operational challenges or increased costs. This sharp drop raises questions about the company's short-term profitability and stability.
Opportunities
3 points- •Operating within the Pharmaceuticals sector, Gufic BioSciences stands to benefit from the overall growth in healthcare spending, increasing demand for medicines, and advancements in medical research, driving future revenue.
- •As a smaller player with a market cap of ₹3330 Cr compared to larger peers, Gufic BioSciences has significant potential to expand its market share through strategic initiatives, product launches, or geographical expansion.
Threats
4 points- •Gufic BioSciences faces intense competition from larger, well-established players in the pharmaceutical sector, which could limit its market share growth and pricing power, impacting future profitability.
- •The pharmaceutical industry is subject to stringent and evolving regulatory frameworks. Any adverse changes in drug approval processes, pricing controls, or manufacturing standards could significantly impact operations and profitability.
Segment-wise Financial Analysis
Fetching Financials...
Fetching Balance Sheet...
Fetching Cash Flow...
Shareholding Pattern
Loading shareholding data...
Company Insider Trading Activity
No insider trading data available
Corporate Action
Company Announcements
Technical Analysis & Indicators
Standard pivot points - most widely used
Pivot Points (CLASSIC)
| Level | Price | Distance | % Change |
|---|---|---|---|
| R4 | ₹342.45 | +₹53.75 | +18.62% |
| R3 | ₹320.60 | +₹31.90 | +11.05% |
| R2 | ₹308.80 | +₹20.10 | +6.96% |
| R1 | ₹298.75 | +₹10.05 | +3.48% |
| PIVOT | ₹286.95 | -1.75 | -0.61% |
| CURRENT | ₹288.70 | - | - |
| S1 | ₹233.20 | -₹55.50 | -19.22% |
| S2 | ₹255.05 | -₹33.65 | -11.66% |
| S3 | ₹265.10 | -₹23.60 | -8.17% |
| S4 | ₹276.90 | -₹11.80 | -4.09% |
CPR Levels
Support
Resistance
S4
N/A
S3
N/A
S2
N/A
S1
N/A
| CPR |
BC: N/AP: N/ATC: N/A
R1
N/A
R2
N/A
R3
N/A
R4
N/A
LTP: N/A
PDH: N/A
PDL: N/A
● Market Sentiment
is trading CPR, indicating
● CPR Width
CPR is
● Opening Range
Day's range: ~
● Price Position
Trading Inside opening range
Delivery Volume Analysis & Trading Activity
Latest Volume-22.6% vs avg
0.47L
(01 Apr 2026)Delivery %-14.4% vs avg
44.9%
(01 Apr 2026)Avg Volume (20D)20-day average
0.61L
(02 Mar - 01 Apr)Avg Delivery %Trend ↓
59.3%
(02 Mar - 01 Apr)Delivery % indicates the percentage of traded volume that resulted in actual delivery. Higher delivery % (>50%) suggests genuine buying interest and stronger hands.
Peer Comparison & Industry Benchmarking
Quick Compare
Largest by Market Cap
Sun Pharmaceutical Industries Ltd
4.12L ₹ Cr
Best Profit Growth
Solara Active Pharma Sciences Ltd
178.00 %
Highest Dividend Yield
RPG Life Sciences Ltd
1.22 %
Peer Comparison
| Company Name |
|---|
 Aarti Drugs Ltd |
 Bliss GVS Pharma Ltd |
 Hikal Ltd |
 Indoco Remedies Ltd |
 IOL Chemicals & Pharmaceuticals Ltd |
 Morepen Laboratories Ltd |
 Orchid Pharma Ltd |
 RPG Life Sciences Ltd |
 Senores Pharmaceuticals Ltd |
 SMS Pharmaceuticals Ltd |
 Solara Active Pharma Sciences Ltd |
 Sun Pharma Advanced Research Company Ltd |
 Sun Pharmaceutical Industries Ltd |
 Unichem Laboratories Ltd |
About
Gufic BioSciences Ltd
Gufic Biosciences Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with a global reach encompassing Africa, Asia, Europe, Australia, North America, and South America. Their core business revolves around the manufacturing and marketing of a diverse range of pharmaceutical products. This includes active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services.
A significant portion of Gufic's manufacturing focuses on APIs and bulk drugs. Their production capabilities span several crucial therapeutic areas. Specifically, they produce antifungals, anesthetics, and immunosuppressants, along with key intermediates used in the synthesis of antifungals. This demonstrates a strong presence in the manufacturing of essential raw materials for the pharmaceutical industry, not just finished products.
Beyond APIs and bulk drugs, Gufic also manufactures lyophilized injections. This advanced pharmaceutical formulation is utilized across a wide spectrum of therapeutic applications. Their lyophilized injection portfolio includes antibiotics, antifungals, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs). This highlights Gufic's ability to deliver a variety of finished dosage forms catering to different patient needs.
In addition to its core API and injection manufacturing, Gufic markets several branded pharmaceutical product lines. These include Criticare, Criticare Life, Ferticare, and Spark Pharmaceuticals, each likely targeting specific therapeutic segments. Furthermore, the company extends its reach into herbal products, aesthetic products under the Aesthaderm brand, Gufic Stridden, and personal care products, diversifying its market presence beyond its pharmaceutical core competencies.
Gufic's distribution network extends to a broad range of customers. The company supplies its products directly to hospital chains and medical facilities, indicating a significant focus on institutional sales and a strong presence within the healthcare system. Their global reach suggests that they either have a robust export division or operate through strategic partnerships in international markets.
COMPANY FACTS - GUFICBIO
Registered Address
1st to 4th Floor, S.M. House, 11 Sahakar Road,, Vile Parle (East),
Mumbai
MAHARASHTRA
IN
Tel: 912267261000
Website:https://gufic.com/
Investor Relations:http://gufic.com/media/investors/annual-reports/
Company Details
Group: Pharmaceuticals, Biotechnology & Life Sciences
Sector: Health Care
Industry: Pharmaceuticals
Exchange: NATIONAL STOCK EXCHANGE OF INDIA
Employees: 1,491
IPO Date: 19/10/2004
MANAGEMENT - GUFICBIO
Mr. Jayesh Choksi
Executive Chairman of the Board, Managing Director
Mr. Pranav Choksi
Chief Executive Officer, Whole Time Director
Mr. Devkinandan Roonghta
Chief Financial Officer
Ms. Ami Shah
Compliance Officer, Company Secretary
Mr. Pankaj Gandhi
Whole Time Director
Dr. Anu Aurora
Non-Executive Independent Director
Mr. Akshya Kumar Mahapatra
Non-Executive Independent Director
Mr. Kamal Seth
Additional Non-Executive Independent Director
Investor Questions Answered
Gufic BioSciences Ltd (GUFICBIO) Stock FAQs
Get answers to the most common questions about Gufic BioSciences Ltd stock price, fundamentals, financial metrics, and investment analysis
The current share price of Gufic BioSciences Ltd (GUFICBIO) is ₹288.7. Today, the stock has gained by ₹14.90 (5.44%), trading in a range of ₹275.15 to ₹297. The stock opened at ₹275.15 with a trading volume of 46,971 shares.
Gufic BioSciences Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹2,937.78 crores, P/E ratio of 51.41, ROE of 3.98%, and ROCE of 13.20%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
The 52-week high price of Gufic BioSciences Ltd (GUFICBIO) is ₹407.85, while the 52-week low is ₹268. Currently trading at ₹288.7, the stock is 14.8% away from its 52-week low and 29.2% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
Whether to buy Gufic BioSciences Ltd stock at ₹288.7 depends on multiple factors. The stock is currently trading with a P/E ratio of 51.41 and P/B ratio of N/A. Today's performance shows a gain of 5.44%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
Gufic BioSciences Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹288.7, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
Gufic BioSciences Ltd's key financial metrics include: P/E Ratio: 51.41, P/B Ratio: N/A, ROE: 3.98%, ROCE: 13.20%, Dividend Yield: 0.00%, EPS: ₹5.68, Book Value: ₹59.94, Debt-to-Equity: 0.56, and Current Ratio: N/A. The company's market cap stands at ₹2,937.78 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
Gufic BioSciences Ltd stock opened at ₹275.15 and is currently trading at ₹288.7, showing a gain of ₹14.90 (5.44%). The intraday high is ₹297 and low is ₹275.15. The trading volume stands at 46,971 shares, indicating moderate market participation today.
Gufic BioSciences Ltd has a Price-to-Earnings (P/E) ratio of 51.41, which means investors are willing to pay ₹51.41 for every ₹1 of earnings. With an EPS of ₹5.68, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
Gufic BioSciences Ltd has a market capitalization of ₹2,937.78 crores, making it a small-cap company. Market cap is calculated by multiplying the current stock price (₹288.7) by the total number of outstanding shares. This metric helps investors understand the company's size, stability, and investment risk profile.
Gufic BioSciences Ltd has a book value of ₹59.94 per share and a Price-to-Book (P/B) ratio of N/A. The current market price is ₹288.7, which is 381.6% above the book value. A P/B ratio below 1 may indicate undervaluation or asset quality concerns.
Gufic BioSciences Ltd has a Return on Equity (ROE) of 3.98% and Return on Capital Employed (ROCE) of 13.20%. ROE measures how efficiently the company generates profits from shareholders' equity, while ROCE indicates how well the company uses its capital to generate profits. These returns may need improvement for better profitability. Higher percentages generally indicate better financial performance.
Gufic BioSciences Ltd operates in the diversified sector and belongs to the general industry. The company competes with other players in this space and its performance is influenced by sector-specific trends, regulatory changes, and market dynamics. Understanding the sector helps investors assess growth potential, cyclical patterns, and industry-specific risks that may impact the stock's performance.
Gufic BioSciences Ltd has a debt-to-equity ratio of 0.56, which measures the company's financial leverage by comparing total debt to shareholders' equity. This moderate ratio indicates balanced use of debt and equity. Lower ratios generally indicate lower financial risk, but optimal levels vary by industry.
Gufic BioSciences Ltd has an Earnings Per Share (EPS) of ₹5.68, which represents the company's profit allocated to each outstanding share. With a current stock price of ₹288.7 and P/E ratio of 51.41, investors are paying 51.41 times the annual earnings per share. The company may need to improve its earnings performance. Track EPS growth over quarters to assess earnings momentum.
Gufic BioSciences Ltd has reported a sales growth of N/A% and profit growth of N/A%. The company may be facing growth challenges or operating in a mature market. Consistent growth over multiple quarters is a positive indicator for long-term investors. Compare these growth rates with industry peers for better perspective.
Gufic BioSciences Ltd has a current ratio of N/A, which measures the company's ability to pay short-term obligations with current assets. A ratio below 1 may indicate potential liquidity concerns. This metric is crucial for assessing the company's working capital management and financial safety.
To analyze Gufic BioSciences Ltd stock, consider: 1) Fundamental Analysis - Review P/E (51.41), ROE (3.98%), debt-to-equity (0.56), and growth rates. 2) Technical Analysis - Check 52-week range (₹268.00 - ₹407.85), moving averages, and chart patterns. 3) Valuation - Compare current price (₹288.70) with book value (₹59.94) and industry peers. 4) Financial Health - Assess current ratio (N/A) and cash flows. 5) Growth Prospects - Evaluate sales growth (N/A%) and profit growth (N/A%). Always diversify and consult a financial advisor.
The face value (or par value) of Gufic BioSciences Ltd share is ₹1.00. Face value is the nominal value of a share as stated in the company's charter and is used for accounting purposes and calculating dividends. The current market price of ₹288.7 is 28770x the face value. Face value remains constant unless the company undergoes a stock split or bonus issue, while market price fluctuates based on demand and supply.
Investing in Gufic BioSciences Ltd carries several risks: 1) Market Risk - Stock price volatility (52-week range: ₹268.00 - ₹407.85). 2) Business Risk - Industry-specific challenges in the sector. 3) Financial Risk - Debt-to-equity ratio of 0.56 indicates leverage. 4) Liquidity Risk - Based on trading volume of 46,971 shares. 5) Valuation Risk - P/E of 51.41 may indicate over/undervaluation. 6) Economic Risk - Macroeconomic factors affecting the industry. Diversify your portfolio and invest only what you can afford to lose.
Gufic BioSciences Ltd operates in the industry with key metrics: P/E ratio of 51.41, ROE of 3.98%, market cap of ₹2,937.78 crores, and dividend yield of 0.00%. To make an informed comparison, analyze these metrics against industry peers considering factors like revenue growth (N/A%), profit margins, debt levels (D/E: 0.56), and market position. Use our peer comparison tool on this page to see detailed side-by-side analysis with competitors.
Target prices for Gufic BioSciences Ltd vary among analysts and depend on multiple factors including earnings projections, industry trends, and market conditions. The stock is currently trading at ₹288.7, with a 52-week range of ₹268.00 to ₹407.85. Based on fundamentals like P/E (51.41), ROE (3.98%), and growth rates, analysts may have different target prices. Always refer to recent research reports from reputed brokerages and make decisions based on your own analysis and risk appetite.
Consider selling Gufic BioSciences Ltd stock when: 1) Target Price Achieved - If the stock reaches your predetermined target from current ₹288.70. 2) Fundamental Deterioration - Declining ROE (currently 3.98%), increasing debt (D/E: 0.56), or falling growth rates. 3) Better Opportunities - Finding stocks with superior risk-reward ratios. 4) Portfolio Rebalancing - When the stock becomes overweight in your portfolio. 5) Changed Investment Thesis - If reasons for buying no longer hold. 6) Stop Loss - If price falls below your risk threshold. Always base decisions on thorough analysis rather than emotions.
Tax implications for Gufic BioSciences Ltd stock investments: 1) Short-term Capital Gains (STCG) - If sold within 1 year, gains taxed at 15% plus cess. 2) Long-term Capital Gains (LTCG) - If held over 1 year, gains above ₹1 lakh taxed at 10% without indexation. 3) Dividend Income - Dividends (current yield: 0.00%) are taxable as per your income tax slab. 4) Securities Transaction Tax (STT) - Applicable on both buy and sell transactions. 5) Intraday Trading - Treated as speculative income, taxed as per slab. Tax laws change periodically, so consult a tax advisor for personalized guidance and latest regulations.
Menu